Dai-ichi Life, a Japanese life insurance company, has partnered with digital health startup Neurotrack on a dementia insurance product. The new product is designed to be coupled with Neurotrack’s Imprint Memory Assessment, which is delivered via a mobile app and measures memory health risk. Participants also are able to access resources to assist them with reducing the risk of decline. The startup's assessment was piloted with 85 adults with subjective cognitive decline over the past two years. After 12 months, the program improved cognitive function scores, decreases in anxiety and depression levels. Other positive impacts reported from the control group: "These initial study results show promise that through early intervention and a personalized program, Alzheimer's risk can be reduced," said Elli Kaplan, co-founder and CEO of Neurotrack. “Just as there have been no easily accessible, reliable diagnostics to determine disease risk in early stages, there have been no cures developed to treat the disease once it has been identified.” Neurotrack plans to follow up their initial study with a randomized controlled trial to determine the success of the program. "Neurotrack is on the cutting edge of developing easy, accessible tools to help people take action on their memory health," said company chief commercial officer Neil Rothstein, who joined the company this year after four years at another digital health startup, 23andMe.
Japanese life insurance company Dai-ichi Life has developed a dementia insurance product, designed to be used with partner Neurotrack’s Imprint Memory Assessment app. It measures users' memory health risk, and offers access to resources which help reduce the risk of cognitive decline. After a 12-month pilot, 86% of the 85 adults participating said the mobile app helped improve cognitive ability.